Moreover, emactuzumab, as monotherapy or plus paclitaxel, as well as LY3022855, plus tremelimumab or durvalumab, are among the CSF-1R antibodies investigated in patients with advanced solid tumors, each showing moderate activity in ovarian cancer patients [167]. Here, CSF1R is linked to ovarian carcinoma.